At the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI), LNC attracted widespread attention and praise for its radionuclide products and research results.
LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. 本次SNMMI年会上，蓝纳成生物取得了令人瞩目的成绩，展示了其核药研发的前沿科技和成果，以下是一些亮点：
At the SNMMI Annual Conference, LNC has achieved remarkable results, showcasing its cutting-edge technology and achievements in radiopharmaceuticals research and development.
177Lu-LNC1004 Clinical Study Progress Report
Prof. Chen Xiaoyuan gave a special report on the clinical research progress and the latest industry trends of the 177Lu-LNC1004 product (FAP-targeted radiotherapy for solid tumors) in the FAP Statellite Syndrome: FAP Ligands for Imaging and Therapy section.
68Ga-DAT5m-LM4 First-In-Human Study
Prof. Zhang Jingjing, as the CMO of LNC, reported the first-in-human study of a novel SSTR antagonist, 68Ga-DATA5m-LM4, in patients with metastatic neuroendocrine tumors. This exciting study won the SNMMI 2023 Travel Award and the SNMMI 2023 International Best Abstract for Singapore Award.
177Lu-LNC1004 Research Awarded
Dr. Fu Hao, the Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University, his research on 177Lu-LNC1004 has been nominated for the Center for Therapy Excellence Young Investigator Award. This study introduces the safety, feasibility, and dosimetry study of 177Lu-EB-FAPI (177Lu-LNC1004) therapeutic dose metastatic radioiodine-refractory thyroid cancer.
18F-LNC1005 Injection Obtained International Recognition
Dr. Xu Weizhi, the Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University, introduced the evaluation of 18F-LNC1005 product in gastric, liver and pancreatic cancer, and compared it with FDG PET/CT. 18F-LNC1005 demonstrated advantages in the evaluation of malignant tumors in the digestive system and was awarded the SNMMI 2023 International Best Abstract for China award at this conference.
The panel discussions provided new ideas and directions for the development of FAP ligands in the fields of imaging and therapy
As a member of the FAP Statelite Symposium: FAP ligands for Imaging and Therapy panel, Prof. Chen Haojun, the Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University, participated in the panel discussion. Through interactive communication among experts, new ideas and directions have been provided for the development of FAP-targeted ligands in the fields of imaging and therapy.
68Ga-LNC1009 Injection in Malignant Tumors Diagnosis
Prof. Chen Haojun also introduced the application of the FAP and integrin receptor-targeted 68Ga-LNC1009 in different types of malignant tumors. Research has found that compared to 18F-FDG and 68Ga-FAPI PET/CT, 68Ga-FAPI-RGD demonstrated better tumor uptake and tumor background ratio (TBR).
68Ga-LNC1009 Injection in Lung Cancer Diagnosis
Dr. Wang Rongxi, the Department of Nuclear Medicine of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, introduced the PET imaging study of 68Ga-LNC1009 in lung cancer patients. Research has found that among lung cancer patients, 68Ga-LNC1009 had high tumor uptake, prolonged tumor retention time, and good tumor to background ratio (TBR); Compared with the 18F-FDG and 68Ga-RGD, 68Ga-LNC1009PET/CT showed a higher detection rate of primary lung cancer lesions, higher tumor uptake, and better metastatic detection.
18F-LNC1001 Injection in Prostate Cancer Diagnosis
Dr. Zang Jie, the Nuclear Medicine Department, the First Affiliated Hospital of Fujian Medical University, introduced the application of the 18F-LNC1001 PET/CT, a PSMA-targeted diagnostic radiopharmaceutical, in medium- and high-risk prostate cancer. The study found that the 18F-Thretide PET/CT has high diagnostic performance for patients with medium- and high-risk prostate cancer.
177Lu-LNC1003 Injection in Prostate Cancer Diagnosis
Prof. Chen Xiaoyuan reported the research progress of 177Lu-LNC1003 injection (targeting prostate specific membrane antigen (PSMA)) at the meeting, and presented the preclinical and clinical data of 177Lu/225Ac-LNC1003 for radioligand therapy for prostate cancer. The performance of this product in the treatment of prostate cancer is better than the FAD approved 177Lu-PSMA-617 injection, and 177Lu-EB-PSMA injection that was previously developed by LNC’s team.
These achievements presented at the SNMMI annual meeting once again demonstrate the innovative ability and technological strength of LNC in the fields of nuclear medicine and oncology radiotheranostics. The breakthrough research of LNC has brought new hope to cancer patients and also showed the international influence and competitiveness of China's nuclear medicine.
LNC will continue to strengthen innovation, provide more accurate and effective treatment plans for cancer patients, and promote the development of nuclear medicine globally.
These achievements of LNC have not only earned the company a reputation, but also set an example for China's nuclear medicine and biotechnology industries, demonstrating China's profound strength and innovative spirit in this field.
We look forward to maintaining LNC’s high-quality R&D standards in the future, and bringing more innovative treatment options to patients worldwide.
